v3.26.1
Overview and Basis of Presentation (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
Mar. 31, 2021
May 31, 2024
Jun. 30, 2026
Disposal Group, Including Discontinued Operations [Line Items]      
Cash, cash equivalents, and marketable securities     $ 1,000.0
Vorasidenib | Contingent Payments and Royalty Rights      
Disposal Group, Including Discontinued Operations [Line Items]      
Sale of royalty interests, percentage sold   100.00%  
Milestone payment for achievement of specified ex-U.S. commercial milestone event   $ 1,000.0  
Royalty percent for sales over $1 billion (as a percent)   12.00%  
Percentage of royalty rights retained   3.00%  
Oscotec Inc.      
Disposal Group, Including Discontinued Operations [Line Items]      
Upfront payment     25.0
Contingent consideration     $ 140.0
Discontinued Operations, Disposed of by Sale | Vorasidenib | United States | Agios Oncology Business      
Disposal Group, Including Discontinued Operations [Line Items]      
Contingent royalty payment 15.00%